A University at Buffalo-led team of researchers has developed a method for producing advanced nanoparticles that could ...

A campaign active since last November has been targeting Python developers building Telegram bots with trojanized Pyrogram ...

A new theory suggests many age-related diseases may actually start decades before symptoms appear. Researchers say early-life damage — from infections, injuries, or genetic mutations — can remain ...

NEW YORK — Federal prosecutors have charged two men with using artificial intelligence to create nude videos and photos of female celebrities under a newly enacted law meant to halt the spread of ...

You can now ask the Gemini app to directly generate “downloadable and ready-to-share files.” Google wants you to “quickly move from a brainstorm to a complete ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. OpenAI wants you to know how good its latest image generator is —and it has a few fake screenshots and ...

OpenAI (OPENAI) introduced ChatGPT Images 2.0 on Tuesday, which improves on the quality of the images, reduces the error rate, and allows users to generate multiple ...

Imtiaz Tyab is a CBS News senior foreign correspondent based in London and reports for all platforms, including the "CBS Evening News," "CBS Mornings," "CBS Sunday Morning" and CBS News 24/7. He has ...

The co-founder of Super Micro Computer and two others were charged with diverting $2.5 billion worth of servers with Nvidia’s artificial intelligence chips to China, in violation of US laws barring ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate:Biomedicines has already earmarked $300 million of the IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (jxfzsy/iStock/Getty Images Plus) ...